CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer.Thomas Powles,Maria Jose Mendez-Vidal,Alejo Rodriguez-Vida, Begoha Perez-Valderrama,Emilio Esteban,Fiona Thistlethwaite,Poulam M. Patel,Urbano Anido Herranz,Gopalakrishnan Srinivasan, Abdel Hamid,James Larkin,Christy Ralph, Stefan N. Symeonides,Javier Puente,Ryan Hartmaier,Aleksandra Markovets,Aaron Prendergast,Kelly Mousa,Cristina SuarezJOURNAL OF CLINICAL ONCOLOGY（2022）引用 0|浏览26暂无评分关键词renal cancer,durvalumab,savolitinib,three-armAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
